skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension

(3179) Views  (474) Full article downloads

Authors: Mark Greathouse

Published Date March 2006 Volume 2006:2(4) Pages 401 - 409
DOI: http://dx.doi.org/10.2147/VHRM.S

Mark Greathouse

South Hills Cardiology Associates of Pittsburgh, Pittsburgh, PA, USA

Abstract: In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When using combination therapy, antihypertensive agents with complementary mechanisms of action are recommended, for example, an angiotensin receptor blocker (ARB) in combination with hydrochlorothiazide (HCTZ), a β-blocker + HCTZ, an ACE inhibitor + HCTZ, or a calcium channel blocker + an ACE inhibitor. One such combination is olmesartan medoxomil + HCTZ, which is available as fixed-dose, single-tablet combinations for once-daily administration. In clinical trials, olmesartan medoxomil/HCTZ reduced systolic BP (SBP) and diastolic BP (DBP) to a greater extent than either component as monotherapy. A clinical study in patients with Stage 1 or 2 hypertension showed that olmesartan medoxomil/HCTZ achieved a similar mean reduction in DBP, but a significantly greater mean reduction in SBP and higher rate of BP control (<140/90 mmHg) than observed with losartan/HCTZ, at US/European-approved starting doses. In a non-inferiority trial, the antihypertensive efficacy of olmesartan medoxomil/HCTZ was comparable to that of atenolol/HCTZ. Furthermore, indirect comparisons have shown that olmesartan medoxomil/HCTZ compares favorably with other antihypertensive combination therapies, including other ARB/HCTZ combinations and amlodipine besylate/benazepril. Olmesartan medoxomil/HCTZ is generally well tolerated. In conclusion, olmesartan medoxomil/HCTZ is an effective and well-tolerated combination antihypertensive therapy that results in significant BP reductions and BP control in many patients.

Keywords: olmesartan medoxomil, hydrochlorothiazide, angiotensin II receptor blocker, hypertension








Readers of this article also read:

Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension
Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
Coronary computed tomographic angiography (CCTA) in community hospitals: “current and emerging role”
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits
Corrigendum
Erratum
Current state of cardiac rehabilitation in Germany: patient characteristics, risk factor management and control status, by education level
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University